Wer viel Geld verdienen will kauft jetzt Nastech Pharma - 500 Beiträge pro Seite

[Yalla]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Lanzelotte]

Hi Yalla,

sorry - aber diese Kindergartenspielchen solltest Du
lieber lassen.

Entweder sagen was Du meinst zu wissen, oder
Schauze halten.

[MSolver]

@Yalla
substanzeloser Pus(c)her!

schon eine dumme Sache von Dir, oder meinst du die Meldung von vorgestern:

Lead Formulation Candidate Achieves Mean Peak Plasma Level Concentrations In Significantly Less Time Than Stadol NS(R)
HAUPPAUGE, N.Y., June 15 /PRNewswire/ -- Nastech Pharmaceutical Company Inc (Nasdaq: NSTK - news) today announced the results of pilot Phase I studies of an intranasal formulation that improves the nasal absorption of butorphanol tartrate, the active ingredient in Stadol NS®. The new formulation is primarily targeted to provide relief of acute migraine pain faster than Stadol NS® and possibly reduce its side effects profile. Nastech plans to initiate and complete pilot Phase II clinical efficacy studies of the new formulation this year.

``Our new formulation provides a mean peak plasma level within one-third the time of Stadol NS® as noted in the PDR (Physician Desk Reference), potentially resulting in faster relief of acute migraine pain,`` stated Charan Behl, Ph.D., Executive Vice President of Research and Development of Nastech. ``In our pilot Phase II efficacy studies we will test this new formulation for the rapid relief of acute migraine and seek to improve the formulation by possibly reducing the dose administered to patients.``

Dr. Behl added that Nastech has filed patent applications to protect its proprietary position and is seeking a licensing partner to jointly develop and market this improved product.

Stadol NS® is the only FDA-approved opioid nasal product indicated for moderate-to-severe pain, including acute migraine. It is licensed by Nastech to Bristol-Myers Squibb and posted sales of approximately $100 million in 1999. According to a report by SG Cowen, the migraine market is projected to grow from $1.5 billion to $3.6 billion by 2003.

Nastech Pharmaceutical Company Inc is utilizing its proprietary STA-T(TM) process to administer intranasally for systemic effect a portfolio of drugs for indications that are mediated through the central nervous system, including scopolamine for the prevention and treatment of motion sickness, apomorphine for the treatment of sexual dysfunction, and morphine for the treatment of moderate-to-severe pain, including breakthrough pain. Nastech is also exploring the feasibility of delivering certain macromolecules intranasally.

The Company has R&D collaborations and commercial partnerships with several pharmaceutical companies, including Bristol-Myers Squibb and Schwarz Pharma. Nastech`s most significant commercial development program is intranasal apomorphine for the treatment of erectile dysfunction, which has shown positive results in pilot Phase II clinical efficacy trials. Additional information on Nastech and its products is available at http://www.nastech.com.

Stadol NS® is a trademark owned by Bristol-Myers Squibb.

This press release may contain forward-looking statements that reflect the Company`s intentions, expectations or beliefs concerning future events, including, but not limited to, expectations with respect to FDA approval of new products, technology and product development milestones, the ability of the Company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales and the sufficiency of the Company`s cash flow for future liquidity and capital resource needs. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company`s research and development program.


Naja, ist ja schon im Kurs drin!

[Yalla]

Wollte mal ein paar reaktionen sehen.


Mir wurde von einem VBänkler zugetragen, dass etwas positives in der Luft sei.
Konkretes konnte er mir auch nicht sagen, deswegen habe ich einmal ein bißchen (klitztkleines bißchen) gepuscht.

Viel ist nicht bei rausgekommen

Sorry, kommt nicht wieder vor.

Yalla, Yalla Yallaman

[nastechler]

guten morgen zusammen.

bin seit längerem in nastech investiert und denke das wirs die aktie der nächsten jahre. kursziel für mich bis 2002 100 euro.

was meint ihr??

gruß nastechler

[bullgerri]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[nastechler]

hi,
das mit dem kz von nastech 100euro ende 2001 habe ich vom österreichischen börsenbrief, der sein kz mit 70dollar angegeben hat. wenn das mit dem potenzspray stimmt, dann ergeben sich ungeahnte möglichkeiten für nastech.

gruß euer nastechler

[ecc83]

Weiss irgendjemand etwas neues ?? Kursziel stammt vom Wiener Börsenbrief, der einen sehr fundieerten Artikel
gebracht hat ! Siehe im Board !!